Insulin glargine biosimilar (Yifan Pharma)

甘精胰岛素生物类似药（亿帆医药）

Report date: 2025/06/24 15:11:41

Base Information

Drug NameInsulin glargine biosimilar (Yifan Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYifan Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYifan Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A